Evaluation of a new circulating tumor cell (CTC) platform to predict response and survival in metastatic urothelial carcinoma (UC) patients receiving cabozantinib (cabo).

被引：35

作者：

Apolo, Andrea Borghese

Lee, Min-Jung

Tomita, Yusuke

Lee, Sunmin

Agarwal, Piyush K.

Jackson, Gloria

Francis, Deneise C.

Lamping, Elizabeth

Buford, Lauren

Tomita, Saori

Mackall, Katherine

Parnes, Howard L.

Dahut, William L.

Gulley, James L.

Trepel, Jane B.

机构：

[1] NCI, NIH, Bethesda, MD 20892 USA

[2] NCI, Dev Therapeut Branch, NIH, Bethesda, MD 20892 USA

[3] NCI, Dev Therapeut Branch, Ctr Canc Res, NIH, Bethesda, MD 20892 USA

[4] NCI, Dev Therapeut Branch, Ctr Canc Res, NIH, Bethesda, MD 20892 USA

[5] NCI, Genitourinary Malignancies Branch, NIH, Bethesda, MD 20892 USA

[6] NCI, Dev Therapeut Branch, NIH, Bethesda, MD 20892 USA

[7] NCI, Canc Prevent Div, NIH, Bethesda, MD 20892 USA

[8] NCI, NIH, Bethesda, MD 20892 USA

[9] NCI, Dev Therapeut Branch, Ctr Canc Res, NIH, Bethesda, MD 20892 USA

来源：

关键词：

D O I：

10.1200/jco.2015.33.15_suppl.e15501

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 [肿瘤学];

摘要：

e15501

引用

页数：1